Trial Profile
Predictors of Response to Iron and Erythropoietin Stimulating Agents
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Epoetin beta (Primary) ; Iron sucrose (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Acronyms PRIME
- 10 Sep 2018 New trial record